证券代码：600867 证券简称：通化东宝 公告编号：2025-074 通化东宝药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 18 日至 11 月 24 日前登录上证路演中心网站首 页点击"提问预征集"栏目或通过公司邮箱（thdb600867@thdb.com）进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 通化东宝药业股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日 发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 25 日 14:00-15:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务指标的具体情 ...

关于计提资产减值准备和核销资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通化东宝药业股份有限公司（以下简称"公司""通化东宝"）于 2025 年 10 月 27 日召开第十一届董事会第十九次会议，审议通过了《关于计提资产减值准 备和核销资产的议案》，为了更加客观、公正地反映公司财务状况和资产价值， 根据《企业会计准则》等相关规定，结合企业实际经营情况和资产现状，对 2025 年 9 月 30 日相关资产进行了减值迹象的识别，对于其中已出现减值迹象的进行 了减值测试，并根据测试结果计提相关资产减值准备，在 2025 年 1-6 月已计提 资产减值准备的基础上，公司 2025 年 7-9 月计提资产减值准备和核销资产的具 体情况如下： 证券代码：600867 证券简称：通化东宝 公告编号：2025-073 通化东宝药业股份有限公司 一、本次计提资产减值准备和核销资产的概述 为更加真实、准确地反映公司 2025 年第三季度的财务状况、资产价值及经 营成果，基于谨慎性原则，公司对相关资产进行了减值测试。根据减值测试结果， ...

第十一届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 通化东宝药业股份有限公司（以下简称"公司"或"通化东宝"）第十一届 董事会第十九次会议，于 2025 年 10 月 27 日以通讯方式召开，会议通知于 2025 年 10 月 17 日，以书面、电子邮件等形式发出。本次会议应参加会议董事 9 人， 实际出席会议董事 9 人，会议由董事长李佳鸿先生主持，监事及高级管理人员列 席了会议。会议符合《公司法》和《公司章程》的有关规定，所作决议合法有效。 会议审议并通过了如下决议： （二）审议通过了《关于计提资产减值准备和核销资产的议案》。 证券代码：600867 证券简称：通化东宝 公告编号：2025-072 通化东宝药业股份有限公司 二、董事会会议审议情况 （一）审议通过了《2025 年第三季度报告》； 表决结果：同意 9 票 反对 0 票 弃权 0 票 本议案已经公司董事会审计委员会审议通过。 内容详见公司于 2025 年 10 月 28 日在中国证券报、上海证券报及上海证券 ...

Group 1 - The company Tonghua Dongbao announced a provision for asset impairment totaling 63.49 million yuan for the period from July to September 2025, with an asset write-off amounting to 51.54 million yuan, which will reduce the net profit attributable to shareholders by approximately 107 million yuan after tax effects [1][1][1] - For the first half of 2025, the revenue composition of Tonghua Dongbao was as follows: 98.59% from the pharmaceutical industry, 1.27% from other businesses, and 0.14% from the real estate sector [1][1][1] - As of the report date, Tonghua Dongbao's market capitalization stood at 17.6 billion yuan [1][1][1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 通化东宝药业股份有限公司 2025 年第三季度报告 证券代码：600867 证券简称：通化东宝 通化东宝药业股份有限公司 2025 年第三季度报告 通化东宝药业股份有限公司 2025 年第三季度报告 | 经营活动产生的现金流 | 不适用 | 不适用 | 380,247,605.21 | | 68.88 | | | --- | --- | --- | --- | --- | --- | --- | | 量净额 | | | | | | | | 基本每股收益（元/股） | 0.50 | 525.00 | 0.61 | | 不适用 | | | 稀释每股收益（元/股） | 0.50 | 525.00 | 0.61 | | 不适用 | | | 加权平均净资产收益率 | 14.91 | 增加 12.39 | 17.77 | 增加 ...

Core Viewpoint - Tonghua Dongbao (600867.SH) reported significant growth in revenue and net profit for the third quarter of 2025, driven by increased sales of insulin analog products and successful overseas business expansion [1] Financial Performance - For the first three quarters, the company achieved a revenue of 2.18 billion yuan, representing a year-on-year increase of 50.55% [1] - The net profit attributable to shareholders for the same period was 1.20 billion yuan [1] - In the third quarter alone, the company recorded a revenue of 806 million yuan, with a year-on-year growth of 13.90% [1] - The net profit for the third quarter reached 984 million yuan, showing a remarkable year-on-year increase of 499.86% [1] Business Drivers - The substantial growth in performance is primarily attributed to the significant increase in sales of insulin analog products, which boosted domestic sales revenue [1] - The company also experienced multiple breakthroughs in overseas business, contributing to increased export revenue [1] - Additionally, the transfer of shares in Te Bao Bio resulted in substantial gains, further enhancing the company's financial performance [1]

Core Insights - Tonghua Dongbao reported a revenue of 806 million yuan for Q3 2025, marking a year-on-year increase of 13.90% [1] - The net profit attributable to shareholders reached 984 million yuan, showing a significant year-on-year growth of 499.86% [1] - Basic earnings per share stood at 0.5 yuan [1] Financial Performance - For the first three quarters, the company achieved a total revenue of 2.18 billion yuan, reflecting a year-on-year growth of 50.55% [1] - The net profit attributable to shareholders for the same period was 1.202 billion yuan [1]

Core Insights - The company reported a third-quarter revenue of 806 million, representing a year-on-year increase of 13.90% [1] - The net profit for the third quarter reached 984 million, showing a significant year-on-year growth of 499.86% [1] - For the first three quarters, the total revenue amounted to 2.18 billion, reflecting a year-on-year increase of 50.55% [1] - The net profit for the first three quarters was 1.202 billion [1]

Core Viewpoint - Tonghua Dongbao has received approval from the Indonesian Food and Drug Authority for the registration of its Aspart Insulin Injection, marking a significant step in the company's international expansion and addressing the growing diabetes treatment needs in Indonesia [1][2]. Group 1: Product Approval and Market Expansion - The approval of Aspart Insulin Injection allows Tonghua Dongbao to sell this product in Indonesia, a major market, following its previous success in Myanmar [1]. - The company has been accelerating its internationalization efforts, achieving important milestones in markets such as Uzbekistan, Nicaragua, Myanmar, and Indonesia this year [2]. - The approval signifies a shift from a focus on raw human insulin to a more diverse product portfolio, including both raw materials and formulations, establishing a robust overseas product system [2]. Group 2: Market Demand and Patient Needs - Indonesia has a rising demand for medical services, with the International Diabetes Federation reporting that the number of diabetes patients aged 20-79 is expected to reach 20.43 million in 2024, with a prevalence rate of 11.0% [1]. - There is a significant gap in diabetes diagnosis and treatment in Indonesia, with 73.2% of diabetes patients undiagnosed, highlighting the urgent need for effective treatment options [1]. Group 3: Future Strategy and Goals - Tonghua Dongbao plans to leverage its production advantages to provide safe, effective, and affordable medical products for endocrine patients globally, aiming to expand its overseas sales [3]. - The company intends to continue registering its insulin products in more countries, starting from Indonesia and Myanmar, and is also focused on advancing the regulatory processes for its products in the U.S. and Europe [3].

Core Viewpoint - Tonghua Dongbao has received the drug registration certificate for insulin aspart injection from the Indonesian Food and Drug Authority, indicating a significant regulatory approval for the company’s product in the Indonesian market [1] Group 1 - The company announced the receipt of the drug registration certificate on October 24 [1] - The registration number for the insulin aspart injection is DKI2570600143A1 [1]